OABI · XBRL financial data

OmniAb financial statements, every fiscal year

The same tables from 5 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (OABI's year ends in late December)

In thousands of dollars	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	34,748	59,077	34,164	26,391	18,666
Research and development	39,232	48,364	56,525	55,110	47,754
General and administrative	16,947	24,903	33,313	30,741	29,215
Total operating expenses	70,357	85,725	103,583	100,893	87,635
Other operating income (expense)	(1,210)	592	(191)	2,365	2,549
Operating income (loss)	(35,609)	(26,648)	(69,419)	(74,502)	(68,969)
Interest income	0	587	5,055	3,106	2,660
Interest expense	7	0	—	—	—
Other income (expense)	1,266	0	1	(15)	15
Income tax expense (benefit)	(7,308)	(3,727)	(13,744)	(9,378)	(1,515)
Net income (loss)	(27,042)	(22,334)	(50,619)	(62,033)	(64,779)
Earnings per share, basic USD per share	(0.33)	(0.26)	(0.51)	(0.61)	(0.57)
Earnings per share, diluted USD per share	(0.33)	(0.26)	(0.51)	(0.61)	(0.57)
Weighted average shares, basic thousands of shares	82,612	85,318	99,683	102,365	113,635
Weighted average shares, diluted thousands of shares	82,612	85,318	99,683	102,365	113,635

Fiscal years (OABI's year ends in late December)

In thousands of dollars	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	190	33,390	16,358	27,598	25,524
Marketable securities	0	54,875	70,625	31,836	28,501
Accounts receivable	21,136	30,290	3,844	5,272	7,390
Inventory	—	—	—	48	823
Prepaid and other current assets	1,406	6,395	4,074	3,432	3,926
Total current assets	935	124,950	94,901	68,138	65,341
Property and equipment, net	6,795	19,979	18,249	15,492	9,428
Right-of-use asset	13,332	21,483	19,884	17,789	15,545
Goodwill	83,979	83,979	83,979	83,979	83,979
Total assets	236,685	421,212	375,225	325,558	300,914
Accounts payable	15	2,971	4,411	2,297	1,879
Accrued liabilities	3,747	5,557	7,068	6,141	6,291
Total current liabilities	438	26,022	23,116	15,088	16,254
Lease liability, non-current	13,272	24,016	22,075	19,382	16,455
Total liabilities	8,488	79,839	60,640	37,940	33,887
Retained earnings (accumulated deficit)	(7,554)	11,252	(39,367)	(101,400)	(166,179)
Total stockholders' equity	(7,554)	341,373	314,585	287,618	267,027
Total liabilities and equity	236,685	421,212	375,225	325,558	300,914
Common shares outstanding (cover page) thousands of shares	0	115,585	117,126	122,135	144,783

Fiscal years (OABI's year ends in late December)

In thousands of dollars	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(27,042)	(22,334)	(50,619)	(62,033)	(64,779)
Stock-based compensation	15,065	18,322	24,820	21,499	15,824
Depreciation and amortization	16,252	18,249	19,497	23,583	21,754
Net cash from operating activities	(5,672)	(3,587)	2,347	(39,664)	(36,455)
Purchases of property and equipment	4,070	17,168	1,644	1,875	565
Net cash from investing activities	(4,025)	(73,313)	(18,376)	37,884	6,467
Proceeds from issuing common stock	0	96,242	0	11,369	0
Net cash from financing activities	9,697	110,739	(892)	13,020	27,914
Net change in cash	0	33,839	(16,921)	11,240	(2,074)

SIC 8731 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 8731 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
OmniAb	22,883	3,993	10,575*	145.9M	—	Q3 FY26 10-QSep 30, 2026
NRC Health	3,327	35,392	1,386*	22.1M	—	Q2 FY26 10-QJun 30, 2026
Maxcyte	15,042	7,271	(4,661)*	103.2M	22.7 quarters	Q2 FY26 10-QJun 30, 2026
Inotiv	15,180	117,652	(1,070)*	34.9M	14.2 quarters	Q2 FY26 10-QMar 31, 2026
Absci	107,865	not reported	(27,564)*	171.6M	7.3 quarters	Q2 FY26 10-QJun 30, 2026
Neogenomics	139,281	209,254	(8,885)*	129.4M	18.9 quarters	Q3 FY26 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.